Extended Data Fig. 2: Smooth muscle vasoactivity, BBB, Iba1⁺ cell, or BAM engraftment in the mice studied.

a. The NOX peptide inhibitor gp91ds-tat or its scrambled control sgp91ds-tat does not alter the CBF increase induced by neocortical application of adenosine (smooth muscle vasoactivity) in WT, ApoE3-TR, and ApoE4-TR mice, or in WT mice treated with vehicle, rApoE4 or rApoE3. b. BBB permeability to 3kD dextran was not altered in ApoE4-TR mice, with or without i.c.v. administration of CLO. c. CLO does not reduce the number of Iba1⁺ cells. d. Smooth muscle vasoactivity in ApoE3- or 4-TR mice with or without CLO treatment. e. Smooth muscle vasoactivity in Mrc1^Cre+, Mrc1^Cre+/ApoE4^fl/fl, or Mrc1^Cre+/ApoE3^fl/fl treated with tamoxifen alone or with rApoE4 (10 µg/ml). f. Numbers of GFP⁺, CD206⁺, and GFP-CD206 double-positive cells in WT, ApoE3-TR, ApoE4-TR mice transplanted with GFP⁺ BM. g. Smooth muscle vasoactivity in ApoE3, ApoE4, WT BM chimeras. Data were analyzed using one-way or two-way ANOVA with Tukey’s test and are presented as mean±SEM. N = 4-5/group.

Source data